Abstract
Levels of melatonin in mammalian circulation are well documented; however, its levels in tissues and other body fluids are yet only poorly established. It is obvious that melatonin concentrations in cerebrospinal fluid (CSF) of mammals including humans are substantially higher than those in the peripheral circulation. Evidence indicates that melatonin produced in pineal gland is directly released into third ventricle via the pineal recess. In addition, brain tissue is equipped with the synthetic machinery for melatonin production and the astrocytes and glial cells have been proven to produce melatonin. These two sources of melatonin may be responsible for its high levels in CNS. The physiological significance of the high levels of melatonin in CNS presumably is to protect neurons and glia from oxidative stress. Melatonin as a potent antioxidant has been reported to be a neuroprotector in animals and in clinical studies. It seems that long term melatonin administration which elevates CSF melatonin concentrations will retard the progression of neurodegenerative disorders, for example, Alzheimer disease.
Keywords: Melatonin, pineal gland, CNS, CSF, oxidative stress, neurodegenerative disease
Current Neuropharmacology
Title: Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Volume: 8 Issue: 3
Author(s): Dun-Xian Tan, Lucien C. Manchester, Emilio Sanchez-Barcelo, Maria D. Mediavilla and Russel J. Reiter
Affiliation:
Keywords: Melatonin, pineal gland, CNS, CSF, oxidative stress, neurodegenerative disease
Abstract: Levels of melatonin in mammalian circulation are well documented; however, its levels in tissues and other body fluids are yet only poorly established. It is obvious that melatonin concentrations in cerebrospinal fluid (CSF) of mammals including humans are substantially higher than those in the peripheral circulation. Evidence indicates that melatonin produced in pineal gland is directly released into third ventricle via the pineal recess. In addition, brain tissue is equipped with the synthetic machinery for melatonin production and the astrocytes and glial cells have been proven to produce melatonin. These two sources of melatonin may be responsible for its high levels in CNS. The physiological significance of the high levels of melatonin in CNS presumably is to protect neurons and glia from oxidative stress. Melatonin as a potent antioxidant has been reported to be a neuroprotector in animals and in clinical studies. It seems that long term melatonin administration which elevates CSF melatonin concentrations will retard the progression of neurodegenerative disorders, for example, Alzheimer disease.
Export Options
About this article
Cite this article as:
Tan Dun-Xian, C. Manchester Lucien, Sanchez-Barcelo Emilio, D. Mediavilla Maria and J. Reiter Russel, Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System, Current Neuropharmacology 2010; 8(3) . https://dx.doi.org/10.2174/157015910792246182
| DOI https://dx.doi.org/10.2174/157015910792246182 |
Print ISSN 1570-159X |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Simple Choline Esters as Potential Anti-Alzheimer Agents
Current Pharmaceutical Design Synthesis of New Tetra Triazole Functionalized Calix[4]resorcinarene and Chemosensing of Copper Ions in Aqueous Medium
Current Organic Chemistry Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Changes in Peripheral Blood Biomarkers with Aging and Neurodegenerative Disorders
Current Aging Science Dimerization of C-terminal Truncations of α-synuclein and its Effect on the Aggregation Propensity: A Potential of Mean Force Study
Current Chemical Biology Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets NMNAT Expression and its Relation to NAD Metabolism
Current Medicinal Chemistry Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Joint Occurrence of Pain and Sleep Disturbances in People with Dementia. A Systematic Review
Current Alzheimer Research Synthesis, Antioxidant, Anticancer and Antiviral Activities of Novel Quinoxaline Hydrazone Derivatives and their Acyclic C-Nucleosides
Medicinal Chemistry Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Allosteric Modulation of Nicotinic Acetylcholine Receptors: The Concept and Therapeutic Trends
Current Pharmaceutical Design Quinolinic Carboxylic Acid Derivatives as Potential Multi-target Compounds for Neurodegeneration: Monoamine Oxidase and Cholinesterase Inhibition
Medicinal Chemistry Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets A Translational View of Peptide Treatment of Neurological Disorders
Current Medicinal Chemistry Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Amyloidophilic Compounds for Prion Diseases
Infectious Disorders - Drug Targets

